Patient Support

Orphalan is committed to helping patients 
access CUVRIOR.

To support people with WD prescribed CUVRIOR, Orphalan developed the Navigator Program™, a no-cost offering for your entire treatment journey.

Program Offerings

Dedicated Care Coordinator

Getting started on a specialty medication can be challenging. A dedicated Care Coordinator is trained to help you navigate this process by providing you with education and support about accessing your medication.   

Quick Start Program

You may experience insurance delays. The Quick Start Program can help you start treatment while sorting out coverage-related questions.

Enrollment and eligibility review required.

Co-pay Program

If eligible, you may pay as little as $0 per month for CUVRIOR. Commercially insured patients with a valid prescription for CUVRIOR may be eligible to participate in this program.

Terms and Conditions apply.

Patient Assistance Program

Are you uninsured or underinsured for CUVRIOR? The Patient Assistance Program may help.    

Enrollment and financial assessment required to confirm eligibility.    
If you have questions about the Navigator Program™, please get in touch with a Care Coordinator at 1-877-995-ORPH (6774) 

Talk to your provider about CUVRIOR

Your healthcare provider can help you decide if CUVRIOR is right for you. Use the CUVRIOR discussion guide to explore if CUVRIOR may be right for you.
Sign up to receive to helpful news and updates.
Sign Up
Find community through the Wilson Disease Association
Learn More
Wilson Disease Association Nutrition Guidance
Learn More
CUVRIOR patient education brochure
Download

What could CUVRIOR mean for you?

Learn more and prepare to talk to your doctor today by downloading 
our CUVRIOR discussion guide.

INDICATION

CUVRIOR is a prescription medicine used to treat adults with stable Wilson Disease who are de-coppered and able to take penicillamine. Wilson Disease is a condition where the body stores too much copper. CUVRIOR is a chelating medicine which binds copper in the blood stream and eliminates it in the urine to help reduce excess copper in the organs.

IMPORTANT SAFETY INFORMATION

  • Do not use CUVRIOR if you are allergic to trientine or to any of the ingredients in CUVRIOR.
  • Your Wilson Disease symptoms could get worse when you start treatment. This could happen because too much copper is removed from the body in a short period of time. Your doctor may need to reduce your dose or stop CUVRIOR treatment.
  • Copper deficiency may develop following treatment with CUVRIOR. Your doctor will do tests to monitor your urine and blood for copper.
  • Iron deficiency may develop while taking CUVRIOR. If this happens, your doctor may tell you to take iron supplements for a limited time.
  • Allergic reactions, such as a rash can occur. If a rash or other allergic reaction occurs, contact your doctor immediately or get emergency help.
  • The most common side effects are pain in the abdomen, change in bowel habits, rash, hair loss (alopecia), and mood swings.

Take CUVRIOR at least 1 hour apart from any other oral medicine. Tell your doctor about all the medicines you're taking, including over-the-counter medicines, vitamins, and herbal supplements. Avoid taking supplements when taking CUVRIOR. Taking CUVRIOR with mineral supplements (e.g., iron, zinc, calcium, magnesium) can reduce the effectiveness of CUVRIOR. If iron supplementation is necessary, take CUVRIOR at least 2 hours before or 2 hours after taking iron; for other mineral supplements (e.g., zinc, calcium, magnesium), take CUVRIOR at least 1 hour before or 2 hours after. Do not start or stop any medicines while taking CUVRIOR without talking to your doctor.

These are not all the possible side effects of CUVRIOR. You are encouraged to report negative side effects of prescription drugs. Contact Orphalan at 1-800-961-8320 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

Expand

INDICATION

CUVRIOR is a prescription medicine used to treat adults with stable Wilson Disease who are de-coppered and able to take penicillamine. Wilson Disease is a condition where the body stores too much copper. CUVRIOR is a chelating medicine which binds copper in the blood stream and eliminates it in the urine to help reduce excess copper in the organs.

IMPORTANT SAFETY INFORMATION

  • Do not use CUVRIOR if you are allergic to trientine or to any of the ingredients in CUVRIOR.
  • Your Wilson Disease symptoms could get worse when you start treatment. This could happen because too much copper is removed from the body in a short period of time. Your doctor may need to reduce your dose or stop CUVRIOR treatment.
  • Copper deficiency may develop following treatment with CUVRIOR. Your doctor will do tests to monitor your urine and blood for copper.
  • Iron deficiency may develop while taking CUVRIOR. If this happens, your doctor may tell you to take iron supplements for a limited time.
  • Allergic reactions, such as a rash can occur. If a rash or other allergic reaction occurs, contact your doctor immediately or get emergency help.
  • The most common side effects are pain in the abdomen, change in bowel habits, rash, hair loss (alopecia), and mood swings.

Take CUVRIOR at least 1 hour apart from any other oral medicine. Tell your doctor about all the medicines you're taking, including over-the-counter medicines, vitamins, and herbal supplements. Avoid taking supplements when taking CUVRIOR. Taking CUVRIOR with mineral supplements (e.g., iron, zinc, calcium, magnesium) can reduce the effectiveness of CUVRIOR. If iron supplementation is necessary, take CUVRIOR at least 2 hours before or 2 hours after taking iron; for other mineral supplements (e.g., zinc, calcium, magnesium), take CUVRIOR at least 1 hour before or 2 hours after. Do not start or stop any medicines while taking CUVRIOR without talking to your doctor.

These are not all the possible side effects of CUVRIOR. You are encouraged to report negative side effects of prescription drugs. Contact Orphalan at 1-800-961-8320 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.